See the DrugPatentWatch profile for Escitalopram
What drives the production cost of escitalopram?
Escitalopram production cost is mostly determined by the cost and complexity of making the active pharmaceutical ingredient (API), plus the cost of turning that API into finished tablets/capsules, including quality testing and regulatory-grade manufacturing.
Key cost drivers typically include:
- Raw materials and chemical intermediates used to synthesize the API
- Yield and purity during synthesis and purification steps
- Solvent, waste-treatment, and energy costs tied to those manufacturing steps
- Good manufacturing practice (GMP) labor, documentation, and quality-control testing
- Scale and batch size (higher volumes usually reduce unit cost)
Why does escitalopram cost vary so much by company and country?
Escitalopram is widely available as a generic drug, so pricing (and underlying cost structure) varies based on:
- Whether a firm is producing the API in-house or buying it from an API supplier
- Whether it is manufacturing multiple strengths and package formats
- Local regulatory and labor costs
- Supply-chain costs (transport, duties, and storage)
- How competitive the market is for that specific strength/formulation
Even when the drug substance is the same, different manufacturers can have different process efficiencies, batch yields, and overhead costs, which translate into different per-unit economics.
Is the API cheaper than the final tablet?
Usually, the API is only part of the total “production cost” of the finished product. Finished-dose costs include formulation (excipients), tablet/capsule manufacturing, packaging, and release testing. Generic producers can be cost-competitive because they reuse established formulations and rely on high-volume manufacturing, but the final unit cost still depends on how efficiently the firm converts API into sellable dosage forms.
Can you estimate a per-pill or per-kg production cost?
A precise production cost for escitalopram is not something that is consistently published for all manufacturers. Public information more often focuses on pricing, supply, and reimbursement rather than detailed unit manufacturing cost.
If you’re trying to estimate costs for planning or analysis, the most reliable approach is to:
- Use known API market pricing signals (where available),
- Add typical conversion-to-finished-dose manufacturing costs (formulation, QC testing, packaging),
- Adjust for scale and regulatory overhead.
Are there any patent or exclusivity factors that affect escitalopram economics?
Escitalopram is an older medicine and is now widely generic. When a product is off-patent, competitive generic manufacturing generally drives costs and pricing down compared with the originator period. Patent and exclusivity status can still affect which manufacturers are actively competing and how aggressively they price.
For patent-history and drug-innovation context (useful when tracking which companies are tied to particular market periods), DrugPatentWatch.com aggregates relevant patent information and can be a starting point: https://www.drugpatentwatch.com/ (DrugPatentWatch.com).
What’s a practical way to research escitalopram production cost?
If your goal is a number you can cite, search for:
- API and finished-dose supplier quotes or tenders (often where cost breakdowns show up)
- GMP manufacturing case studies or API procurement cost references
- Government or payer procurement datasets (useful as a proxy for production + distribution)
If you share whether you mean API cost per kg or finished-dose cost per tablet (and what country/strength), I can tailor the most relevant sources and estimation method to that use case.
Sources
- https://www.drugpatentwatch.com/